Sinco Pharmaceuticals Holdings logo

6833 - Sinco Pharmaceuticals Holdings Share Price

HK$0.51 0.2  45.7%

Last Trade - 26/02/21

Sector
Consumer Defensives
Size
Small Cap
Market Cap £54.0m
Enterprise Value £54.9m
Revenue £139.9m
Position in Universe 4088th / 6135
Bullish
Bearish
Unlock 6833 Revenue
Momentum
Relative Strength (%)
1m +35.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.09%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
950.1 1,096 858.9 806.7 953 1,176 +4.4%
+89.8 +0.4 -77.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, SincoPharmaceuticals Holdings Ltd revenues increased 19% toRMB636.3M. Net income increased from RMB15.2M to RMB32.5M.Revenues reflect Human Albumin Solution segment increase of39% to RMB503.1M. Net income benefited from Interest onbank loans and other borrowi decrease of 89% to RMB1.1M(expense), Bad Debt Written Off/Provision decrease fromRMB5.6M (expense) to RMB1.8M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

6833 Revenue Unlock 6833 Revenue

Net Income

6833 Net Income Unlock 6833 Revenue

Normalised EPS

6833 Normalised EPS Unlock 6833 Revenue

PE Ratio Range

6833 PE Ratio Range Unlock 6833 Revenue

Dividend Yield Range

6833 Dividend Yield Range Unlock 6833 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
6833 EPS Forecasts Unlock 6833 Revenue
Profile Summary

Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated March 16, 2015
No. of Shareholders: n/a
No. of Employees: 104
Sector Consumer Defensives
Industry Food & Drug Retailing
Index
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 1,691,890,585
Free Float (0.0%)
Eligible for
ISAs
SIPPs
+
Address , CHENGDU, China
Web http://www.sinco-pharm.com
Phone +86 28 62912988
Contact ()
Auditors Crowe Horwath (HK) CPA Limited
6833 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 6833
Upcoming Events for 6833
Frequently Asked Questions for Sinco Pharmaceuticals Holdings
What is the Sinco Pharmaceuticals Holdings share price?

As of 26/02/21, shares in Sinco Pharmaceuticals Holdings are trading at HK$0.51, giving the company a market capitalisation of £54.0m. This share price information is delayed by 15 minutes.

How has the Sinco Pharmaceuticals Holdings share price performed this year?

Shares in Sinco Pharmaceuticals Holdings are currently trading at HK$0.51 and the price has moved by 22.81% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sinco Pharmaceuticals Holdings price has moved by -5.45% over the past year.

What are the analyst and broker recommendations for Sinco Pharmaceuticals Holdings?

Of the analysts with advisory recommendations for Sinco Pharmaceuticals Holdings, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Sinco Pharmaceuticals Holdings is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Sinco Pharmaceuticals Holdings next release its financial results?

Sinco Pharmaceuticals Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Sinco Pharmaceuticals Holdings dividend yield?

Sinco Pharmaceuticals Holdings does not currently pay a dividend.

Does Sinco Pharmaceuticals Holdings pay a dividend?

Sinco Pharmaceuticals Holdings does not currently pay a dividend.

When does Sinco Pharmaceuticals Holdings next pay dividends?

Sinco Pharmaceuticals Holdings does not currently pay a dividend.

How do I buy Sinco Pharmaceuticals Holdings shares?

To buy shares in Sinco Pharmaceuticals Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sinco Pharmaceuticals Holdings?

Shares in Sinco Pharmaceuticals Holdings are currently trading at HK$0.51, giving the company a market capitalisation of £54.0m.

Where are Sinco Pharmaceuticals Holdings shares listed? Where are Sinco Pharmaceuticals Holdings shares listed?

Here are the trading details for Sinco Pharmaceuticals Holdings:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 6833
What kind of share is Sinco Pharmaceuticals Holdings?

Based on an overall assessment of its quality, value and momentum, Sinco Pharmaceuticals Holdings is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sinco Pharmaceuticals Holdings share price forecast 2021?

We were not able to load any forecast data for Sinco Pharmaceuticals Holdings.

How can I tell whether the Sinco Pharmaceuticals Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinco Pharmaceuticals Holdings. Over the past six months, the relative strength of its shares against the market has been -1.47%. At the current price of HK$0.51, shares in Sinco Pharmaceuticals Holdings are trading at 31.62% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sinco Pharmaceuticals Holdings PE Ratio?

The Sinco Pharmaceuticals Holdings PE ratio based on its reported earnings over the past 12 months is 12.38. The shares are currently trading at HK$0.51.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Sinco Pharmaceuticals Holdings?

Sinco Pharmaceuticals Holdings's management team is headed by:

Xiangbin Huang - CHM
Qing Wang - NID
Wenfang Liu - NID
Zhizheng Li - SVP
Yifan Li - CFO
Guowei Liu - VOP
Yue Wu - DSL
Fei Peng - CTR
Haibin Hu - OTH
Ling Bai - OTH
Xianghong Li - OTH
Ying Kit Lau - NID
Zhizhong Bai - NID
Min Jin - CCE
Who are the major shareholders of Sinco Pharmaceuticals Holdings?

Here are the top five shareholders of Sinco Pharmaceuticals Holdings based on the size of their shareholding:

Huang (Xiangbin) Individual Investor
Percentage owned: 62.06% (1.05bn shares)
Liu (Sichuan) Individual Investor
Percentage owned: 5.32% (90.0m shares)
Gui (Guoping) Individual Investor
Percentage owned: 1.24% (20.9m shares)
JIn (Min) Individual Investor
Percentage owned: 0.81% (13.7m shares)
Similar to 6833
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.